INOVIO Announces Pricing of Approximately $75 Million Public Offering

1 source1 article First seen 1 day ago Updated 1 day ago United States Truth score 34

Save Like Comments Compare coverage

Summary

PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing…

Description from Amherst Bee.

Who is covering this

Amherst Bee Not rated US 1 day ago
INOVIO Announces Pricing of Approximately $75 Million Public Offering
PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today...

Comments

Comments need JavaScript.

Truth score

34/100Weakly supported

Independent outlets: 1
Source reliability: Not rated
Sides of the spectrum covering it: 0/3
Propaganda risk: 0/100

How well the story is corroborated by independent, reliable outlets across the spectrum. Not a fact-check of each claim. How the truth score works

Coverage by lean

No rated outlets yet

Left: 0
Centre: 0
Right: 0
Not rated: 1

How lean is counted

Source quality

Average reliability: Not rated
Low-credibility outlets: 0%
State media: 0%
Opinion pieces: 0%

Where ratings come from

Where the coverage comes from

United States1

Filter the stories

Sources Ratings and details

INOVIO Announces Pricing of Approximately $75 Million Public Offering

Summary

Who is covering this

Comments